000			03380cam a2200397Ii 4500
001			95132
003			ES-MaUEC
005			20230102112648.0
006			m o d
007			cr cnu|||unuuu
008			170104s2017 sz o 001 0 eng d
020			_a3319430610
020			_a3319430637 _q(electronic bk.)
020			_a9783319430614
020			_a9783319430638 _q(electronic bk.)
020			_z9783319430614 _q(print)
035			_a(OCoLC)967655963 _z(OCoLC)974650592 _z(OCoLC)981852696 _z(OCoLC)1005769262 _z(OCoLC)1011791993
040			_aN$T _cN$T _dEBLCP _dIDEBK _dGW5XE _dN$T _dUAB _dNJR _dYDX _dCOO _dUPM _dOCLCO _dOCLCF _dIOG _dOCLCO _dMERER _dESU _dZ5A _dOCLCO _dJBG _dIAD _dOCLCO _dICW _dOCLCO _dICN _dOCLCQ _dOCLCO _dOTZ _dOCLCQ _dVT2 _dOCLCO _dOCLCQ _dU3W _dOCLCO _dES-MaUEC _bspa
050		4	_aRC280.D5 _b2017 EB
245	0	0	_aImmunotherapy for gastrointestinal cancer _cDavid Kerr, Rebecca Johnson, editors.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aIntroduction to modern immunology -- Cell based therapy? modified cancer cells -- Vaccines for GI cancer -- Antibody delivery of radioactive?warheads? and cytotoxins -- Antibodies which inhibit specific cell pathways -- PD1 and PD1l immune checkpoint inhibitors -- The Role of the JAK/STAT Signaling Pathway in Immunoregulation of Gastrointestinal Cancers -- Hyper mutated colorectal cancer and neoantigen load -- Antibodies which inhibit specific cell pathways, colorectal cancer.
520	3		_aThis book is about the manipulation of the immune system as a therapeutic approach to gastrointestinal cancer and its clinical applications, exploring therapeutic approaches which might be taken under the broad banner of immunotherapy. Starting by introducing concepts of modern immunology, the clinical applications of immunotherapy are then discussed. The reader will learn about the three broad classes of immune therapeutic agents: cell-based treatment; antibody therapy; cytokine application and the key effector cells and mechanisms which might cause tumour rejection. The reverse side of this equation, the genetic and molecular mechanisms which the tumour can use to escape immune control and regulation, is also discussed. Through reviewing the most up-to-date evidence, this volume provides an overview of the important scientific lessons learned from past failure of immunotherapeutics in the clinic and highlights more positive recent data, coupled to practical guidelines for clinical usage. Written by a team of worldwide experts, this is an indispensable guide for medical oncologists, surgical oncologists, radiation therapists, pharmacists, oncology nurse specialists.
650		7	_aMedicina _2embne _0(OCoLC)fst01014893 _0 _9405021
650		7	_aInmunología _0(OCoLC)fst00968006 _0 _2embne _9138330
700	1		_aJohnson, Rebecca, _eeditor literario
700	1		_aKerr, David, _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-43063-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c95132 _d95132 _x1